| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable. L-Leucine-d10 is not used to measure pharmacological activity. It is employed as an internal standard and stable isotope tracer. Its purpose is to facilitate precise quantification of unlabeled L-Leucine in biological samples using mass spectrometry. The pharmacological profile is identical to that of unlabeled L-Leucine.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Not applicable. L-Leucine-d10 itself is not used for measuring biological activity. It is an analytical standard. However, the parent compound L-Leucine is an essential amino acid that increases basal metabolism. It is a potent activator of the mTORC1 signaling pathway. The labeled form is used as a tracer to study the metabolism of leucine itself. |
| ln Vivo |
Not applicable. L-Leucine-d10 is an analytical standard and is not used for in vivo activity assays. However, it can be used as a metabolic tracer to study protein synthesis and amino acid turnover. For this purpose, a tracer dose (e.g., 10-20 mg/kg) is administered, and its incorporation into proteins or its conversion to metabolites is tracked by mass spectrometry.
|
| Enzyme Assay |
L-Leucine-d10 is used as an internal standard for the quantification of L-Leucine. A stock solution is prepared in 0.1 M HCl or methanol. For protein precipitation, 100 uL of a biological sample (plasma, urine) is mixed with 300 uL of ice-cold acetonitrile containing a fixed concentration of L-Leucine-d10 (e.g., 50 ng/mL). After vortexing and centrifugation, the supernatant is transferred to an autosampler vial and analyzed by LC-MS/MS in MRM mode. The mass transitions are: L-Leucine (m/z 132 → 86) and L-Leucine-d10 (m/z 142 → 96). The peak area ratio of L-Leucine to L-Leucine-d10 is used to calculate the concentration from a calibration curve. The 10 Da mass shift ensures no cross-talk with the native analyte.
|
| Cell Assay |
For cellular metabolic flux analysis, cells (e.g., primary hepatocytes or neuronal cells) are cultured in medium containing L-Leucine-d10 (0.1-1 mM) for 0.5-24 hours. The labeled leucine is taken up via amino acid transporters and can be incorporated into cellular proteins. At the end of the labeling period, cells are harvested and lysed. Protein concentration is determined via BCA assay, and proteins are hydrolyzed in 6 M HCl. The hydrolysate is derivatized (e.g., using MTBSTFA for GC-MS or dansyl chloride for LC-MS) to improve volatility. The incorporation of the deuterium label into the amino acid pool and the protein fraction is measured by GC-MS or LC-MS. These data can be used to calculate protein synthesis and degradation rates.
|
| Animal Protocol |
L-Leucine-d10 is used in metabolic tracer studies. Animals (e.g., male Sprague-Dawley rats, 200-250 g) are fasted overnight and then administered a tracer dose of L-Leucine-d10 (e.g., 20 mg/kg) via intravenous or oral administration. Blood samples are collected at predetermined times (e.g., 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose). Plasma is separated, and proteins are precipitated with acetonitrile containing L-Leucine-13C6,15N as a secondary internal standard. The supernatant is analyzed by LC-MS/MS. The clearance rate of the labeled leucine and its conversion to metabolites (e.g., alpha-ketoisocaproate) can be tracked. The data can be used to calculate whole-body protein turnover by kinetic modeling.
|
| ADME/Pharmacokinetics |
L-Leucine-d10 (MW 141.23) is a stable isotope-labeled compound with high isotopic purity (98 atom % D). Its physicochemical properties are identical to those of natural L-Leucine, allowing it to behave identically in biological systems. It is water-soluble and stable. It is intended for use as an internal standard and is not intended for human use.
|
| Toxicity/Toxicokinetics |
L-Leucine-d10 is a non‑toxic, stable isotope‑labeled compound. At the concentrations used as an internal standard (ng/mL levels), it poses no toxicological risk. The unlabeled parent compound, L-Leucine, is an essential amino acid safe for consumption at nutritional levels. The labeled analog has no known acute or chronic toxicity at tracer doses.
|
| References |
|
| Additional Infomation |
Deuterated L-leucine is a deuterated compound.
L-Leucine-d10 is intended for use as an internal standard for the quantification of L-leucine by GC- or LC-MS. It is a high-purity compound with high isotopic enrichment, suitable for research applications in amino acid metabolism and protein turnover studies. CAS: 106972-44-5. |
| Molecular Formula |
C6H3D10NO2
|
|---|---|
| Molecular Weight |
141.23
|
| Exact Mass |
141.157
|
| CAS # |
106972-44-5
|
| Related CAS # |
L-Leucine;61-90-5
|
| PubChem CID |
16213587
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
225.8±23.0 °C at 760 mmHg
|
| Melting Point |
>300 ℃(lit.)
|
| Flash Point |
90.3±22.6 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
0.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H][C@@](C(=O)O)(C([2H])([2H])C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])N
|
| InChi Key |
ROHFNLRQFUQHCH-ZWFPVXGPSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1/i1D3,2D3,3D2,4D,5D
|
| Chemical Name |
(2S)-2-amino-2,3,3,4,5,5,5-heptadeuterio-4-(trideuteriomethyl)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.0806 mL | 35.4032 mL | 70.8065 mL | |
| 5 mM | 1.4161 mL | 7.0806 mL | 14.1613 mL | |
| 10 mM | 0.7081 mL | 3.5403 mL | 7.0806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
